

SB0608/243527/1

BY: Finance Committee

AMENDMENTS TO SENATE BILL 608
(First Reading File Bill)

AMENDMENT NO. 1

On page 1, strike beginning with “limiting” in line 7 down through “testing;” in line 9.

AMENDMENT NO. 2

On page 2, in line 8, strike “(1)”; and strike in their entirety lines 11 through 33, inclusive.

On page 3, in line 31, strike “AND”.

On page 4, in line 1, after “(2)” insert “(I) THE PHARMACOGENOMIC TESTING IS USED TO GUIDE THE SELECTION, DOSING, OR MANAGEMENT OF A MEDICATION FOR AN INDIVIDUAL; OR

(II)”;

and in line 3, after “INTERACTION” insert “;

(3) THE INDIVIDUAL IS BEING TREATED, OR IS EXPECTED TO BE TREATED, WITH A MEDICATION FOR WHICH EVIDENCE-BASED PHARMACOGENOMIC INFORMATION IS AVAILABLE DEMONSTRATING A CLINICALLY MEANINGFUL IMPACT ON DRUG EFFICACY, SAFETY, OR RISK OF ADVERSE EVENTS;

(4) THE PHARMACOGENOMIC TESTING IS CONSISTENT WITH GENERALLY ACCEPTED STANDARDS OF MEDICAL PRACTICE, INCLUDING

CLINICAL GUIDELINES, PEER-REVIEWED MEDICAL LITERATURE, OR DRUG LABELING APPROVED BY THE FEDERAL FOOD AND DRUG ADMINISTRATION;

(5) THE RESULTS OF THE PHARMACOGENOMIC TESTING ARE INTENDED TO BE USED IN CLINICAL DECISION MAKING TO OPTIMIZE THERAPEUTIC OUTCOMES, REDUCE THE LIKELIHOOD OF ADVERSE DRUG REACTIONS, OR AVOID INEFFECTIVE THERAPY; AND

(6) THE PHARMACOGENOMIC TESTING IS COVERED BY THE FEDERAL MEDICARE PROGRAM UNDER A NATIONAL OR LOCAL COVERAGE DETERMINATION ISSUED BY A MEDICARE ADMINISTRATIVE CONTRACTOR”;

On pages 4 and 5, strike in their entirety the lines beginning with line 4 on page 4 through line 9 on page 5, inclusive, and substitute:

“(D) THE FAILURE OF A CARRIER TO PROVIDE COVERAGE FOR A PHARMACOGENOMIC TEST REQUIRED TO BE COVERED UNDER THIS SECTION CONSTITUTES AN ADVERSE DECISION.”

On page 5, in line 10, after “shall” insert “apply to all policies, contracts, and health benefit plans issued, delivered, or renewed in the State on or after January 1, 2027.”

SECTION 3. AND BE IT FURTHER ENACTED, That this Act shall”;

and in line 11, strike “October 1, 2026” and substitute “January 1, 2027”.